Barclays raised the firm’s price target on Terns Pharmaceuticals (TERN) to $27 from $14 and keeps an Overweight rating on the shares. The firm sys TERN-701 demonstrated a potentially best-in-class profile in chronic myeloid leukemia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals price target raised to $22 from $15 at BMO Capital
- Terns Pharmaceuticals price target raised to $35 from $28 at Jefferies
- Enliven being 20% down on Terns news ‘makes no sense,’ says Mizuho
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue
- William Blair upgrades Terns Pharmaceuticals after ‘impressive’ data